TY - JOUR T1 - Oestrogen plus progestin reduced risk of fracture in postmenopausal women JF - Evidence Based Medicine JO - Evid Based Med SP - 82 LP - 82 DO - 10.1136/ebm.9.3.82 VL - 9 IS - 3 A2 - , Y1 - 2004/05/01 UR - http://ebm.bmj.com/content/9/3/82.abstract N2 - Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–38.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In postmenopausal women, does oestrogen plus progestin reduce the risk of fracture? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★☆☆ Rheumatology ★★★★★★☆ Design: randomised placebo controlled trial. Allocation: {allocation concealed*}†. Blinding: blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}†.* Follow up period: mean 5.6 years. Setting: {40 US clinical centres.}† Participants: 16 608 women who were 50–79 years of age (mean age 63 y) and had an intact uterus. {Exclusion criteria included probable survival of <3 years, cancer in the past 10 years, and low haematocrit or platelet counts.}† Intervention: a single table of either conjugated equine oestrogen, 0.625 mg/day and medroxyprogesterone acetate, 2.5 … ER -